回顾：上周9只新股上市，其中6只来自中国，具体如下： 1、生物技术公司——MapLight Therapeutics, Inc. 计划上市时间：2025年10月28日 交易所：NASDAQ 美妍堂(MCTA)以每股4美元，发行了160万股，募集了640万美元。 网塑科技(NPT)以每股5美元，发行了190万股，募集了950万美元。 Agencia Comercial(AGCC)以每股4美元，发行了175万股，募集了700万美元。 Bgin Blockchain (BGIN)以每股6美元，发行了500万股，募集了3000万美元。 Ambitions Enterprise Management (AHMA) 以每股4美元，发行了150万股，募集了600万美元。 SPAC Harvard Ave Acquisition (HAVAU)、Calisu Acquisition (ALISU) 、Miluna Acquisition (MMXTU)、Lafayette Acquisition (LAFAU)分别募集了 1.45亿美元、6000万美元、6000万美元、1亿美元。 此外，9家公司递交招股书，其中2家来自中国， ...

在"科创回归都市"的浪潮中，历史悠久的老城区如何焕发科创活力，点燃发展新引擎？10月24日，第十九届上海金融服务实体经济洽谈会（下称"金洽 会"）"园区行"走进上海虹口，于专场活动中给出了生动答案。 本次活动汇聚张江虹口园智慧健康园、北科创生物技术产业园、北科创星孵化中心等区内多家重点产业园区和孵化载体，共同聚焦 "绿色低碳、生物技 术、健康医疗"三大核心领域，探讨金融如何精准赋能，助力企业破解融资难题，驶入高质量发展快车道。 互动交流环节甫一开始，现场气氛便迅速升温。来自上海同禾工程科技股份有限公司、上海有有电子商务有限公司、上海蓝晶微生物科技有限公司、上 海经海纬象生物材料有限公司、中太能源等多家企业代表争先举手，就经营与融资方面遇到的痛点与堵点现场"问诊"。 "怎么能消除企业与金融机构之间的信息差，确保我们拿到的是最优融资方案？" "我们很多业务面向个人客户，他们在付款时经常遇到支付限额、操作复杂等问题，影响企业资金的及时回笼，有没有什么好的工具或方法可以解决？" 针对企业提出的诸多关切，来自上海市融资担保中心、农业银行上海市分行、人保财险上海分公司、太保财险上海分公司、海通恒信的普惠金融顾问给 予了积 ...

Market Performance - The three major U.S. stock indices collectively rose, with the Dow Jones increasing by 0.50%, the S&P 500 by 0.67%, and the Nasdaq Composite by 0.88% [1] Company Highlights - Intel's stock rose by 5.6% after reporting Q3 revenue that exceeded expectations and returning to profitability [1] - Beyond Meat's shares surged over 16% due to Q3 revenue that was better than market expectations [1] - Adverum Biotechnologies saw its stock increase by over 5% following Eli Lilly's announcement to acquire the company [1] - Procter & Gamble's stock rose nearly 4% as its first fiscal quarter net sales exceeded expectations [1] - Quantum computing stocks experienced gains, with D-Wave Quantum up over 6%, IONQ up over 4%, and both Quantum Computing and Rigetti Computing rising over 3% [1] Industry Developments - JPMorgan Chase plans to allow institutional clients to use Bitcoin and Ethereum as collateral for loans by the end of the year, relying on third-party custodians for token storage [2] - SpaceX is reportedly set to provide satellite communication services for Apple's iPhone, integrating existing satellite functionality into new satellite designs [3] - IBM announced that a key quantum computing algorithm can run on standard AMD chips, demonstrating the algorithm's practicality and cost-effectiveness [4]

外媒注意到 " 保持制造业合理比重 " 全会指出，"十五五"时期是基本实现社会主义现代化夯实基础、全面发力的关键时期，在基本实现社会主义现代化进程中具有 承前启后的重要地位。 全会提出了"十五五"时期经济社会发展的主要目标：高质量发展取得显著成效，科技自立自强水平大幅提高，进一步全面深化 改革取得新突破，社会文明程度明显提升，人民生活品质不断提高，美丽中国建设取得新的重大进展，国家安全屏障更加巩 固。在此基础上再奋斗五年，到二〇三五年实现我国经济实力、科技实力、国防实力、综合国力和国际影响力大幅跃升，人均 国内生产总值达到中等发达国家水平，人民生活更加幸福美好，基本实现社会主义现代化。 美联社23日在报道中提及，四中全会公报称，"'十五五'时期中国发展环境面临深刻复杂变化"，"不确定难预料因素增多"。法国 外贸银行高级经济学家吴卓殷表示，公报表明中国政府有信心通过国内政策工具应对外部挑战。此外，全会提出"加快高水平科 技自立自强""完善收入分配制度"及"加快经济社会发展全面绿色转型"。全会还提出，"坚持扩大内需这个战略基点，坚持惠民生 和促消费"，美联社引述经济学家的话表示，这对中国经济增长很重要。 路透社等 ...

Summary of Evaxion Biotech A/S Update / Briefing (October 22, 2025) Company Overview - **Company**: Evaxion Biotech A/S - **Founded**: 2008 in Copenhagen, Denmark - **Focus**: AI-first company leveraging proprietary AI-Immunology platform for vaccine discovery, design, and development [3][4] Industry Context - **Disease Focus**: Advanced melanoma, a highly aggressive skin cancer with high mortality rates, particularly in metastatic cases [14][15] - **Historical Context**: Prior to 2011, melanoma clinical trials had a high failure rate. Introduction of immunotherapy marked a significant shift in treatment efficacy [14][15] Core Points from the Call AI-Immunology Platform - **Functionality**: Decodes human systems for therapeutic target discovery by integrating genomic, transcriptomic, and proteomic data [3][4] - **Success Rate**: High success in selecting targets that induce potent T-cell responses against cancer cells [4] Clinical Trials - **Phase 1 Trial**: - Conducted on patients with Stage 3B and Stage 4 melanoma. - **Results**: 67% objective response rate (ORR) with 8 out of 12 patients showing response; however, 7 relapsed [8][9] - **Safety**: Well tolerated with mainly grade one and two adverse events [7][8] - **Key Learnings**: Recommended Phase 2 dose set at 200 micrograms; booster administrations included in Phase 2 to sustain T-cell levels [8][9] - **Phase 2 Trial**: - Included treatment-naive patients with Stage 3 unresectable or Stage 4 melanoma [18][19] - **Primary Endpoint**: Conversion from stable disease to partial or complete response [19][20] - **Secondary Endpoints**: Objective response rate, progression-free survival, overall survival, and neoantigen-specific T-cell response [20] - **Study Population**: 17 enrolled patients, predominantly Stage 4 melanoma [23] - **Safety Profile**: Consistent with Phase 1, primarily grade one adverse events [24][25] - **Results**: 75% best objective response rate; 54% conversion rate from stable disease to partial response [30][31] Efficacy and Safety - **T-cell Responses**: 81% of neoantigens induced T-cell responses, an increase from 65% in Phase 1 [31] - **Sustained Responses**: 92% of responders maintained responses at the 24-month mark [37] - **Manufacturing Success**: 100% success rate in vaccine manufacturing for all patients [38] Additional Insights - **Personalized Treatment**: Emphasis on the need for personalized therapies to improve efficacy and reduce toxicity compared to standard treatments [17][18] - **Future Directions**: Potential for further studies to explore the efficacy of personalized vaccines in previously treated melanoma patients and the role of booster doses [68][70] Conclusion - **Encouraging Data**: The results from the Phase 2 trial support the ongoing development of Evaxion's personalized cancer vaccine, EVX-01, in high-risk melanoma [38] - **Next Steps**: Continued evaluation of patient responses and potential adjustments to dosing schedules and treatment regimens based on emerging data [62][63]

轩竹生物涨超18%，创上市以来新高，药捷安康涨超16%，博安生物、同源康医药涨超2%。 (本文来自第一财经) ...

每经AI快讯，10月22日，港股生物技术股大涨，轩竹生物涨超18%，创上市以来新高，药捷安康涨超 16%，博安生物、同源康医药涨超2%。 ...

Group 1 - The core point of the article is that Shengxiang Bio (688289.SH) plans to establish a partnership with Suzhou Weitili New Venture Capital Management Co., Ltd. to set up Changzhou Lingzhong Venture Capital Partnership (Limited Partnership) [1] - The company intends to invest RMB 20 million as a limited partner, accounting for 19.80% of the partnership [1] - The fund will primarily focus on investing in outstanding startups in the healthcare sector, including but not limited to innovative medical devices, biomedicine, advanced biotechnology, and health management [1]

（来源：一度医药） 受该消息影响，Galapagos股价在公告发布后的早盘交易中下跌14%。 转自：一度医药 据路透社消息，生物技术公司加拉帕戈斯（Galapagos，股票代码：GLPG.AS）于周二宣布，因出售细 胞治疗业务的尝试未果，将逐步关停该业务板块。此次业务调整将影响欧洲、中国及美国地区的365个 工作岗位。 这家在阿姆斯特丹上市的企业表示，自今年5月开始为细胞治疗业务探索多种发展方案以来，已收到多 份非约束性报价，但最终评估后认为这些报价均不具备可行性。 Galapagos方面指出，当前逐步终止细胞治疗业务，将资金转而用于构建新疗法研发管线，是更合理的 战略选择。 ...

斯洛克认为，尽管贸易紧张局势继续对全球增长造成轻微拖累，但这些不利因素正日益被技术驱动和工 业动能所抵消——这增加了美国经济增长在未来几个月重新加速的可能性。 斯洛克强调，与人工智能相关的数据中心和能源基础设施的持续扩张，正为企业投资和消费者信心提供 切实支撑。与此同时，股市上涨增强了家庭消费能力。 此外，制造业、国防、生物技术和自动化领域新的资本投入表明，他所谓的"工业复兴"正处于早期阶 段。 智通财经APP获悉，阿波罗全球管理公司首席经济学家托斯滕·斯洛克表示，美国经济可能正在进入一 个比许多人预期更强劲的阶段。在最近给投资者的报告中，阿波罗公司称关键信贷指标正显示出明显的 改善迹象，表明经济深层具有韧性。 斯洛克指出，高收益债券和杠杆贷款的违约率已经见顶，信用卡和汽车贷款的拖欠率也是如此。这位经 济学家将这种转变归因于三个主要因素：贸易战带来的不确定性逐渐消退、人工智能热潮带来的强劲顺 风，以及美国工业活动的全面复苏。 ...